Tagrisso

Osimertinib, sold under the brand name Tagrisso,[3] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[4][5] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.[6] Osimertinib was approved for medical use in the Unit... [wikipedia]